Prostate Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Prostate Cancer, including details on symptoms, genetics, screening, treatment, information.

Volume 3 (2006), Issue 12 (December)

1. Post-therapy changes in PSA as an outcome measure in prostate cancer clinical trials.
   Nat Clin Pract Oncol, 3(12): 658-67. [Abstract] [Full-text]
2. A selective androgen receptor modulator that reduces prostate tumor size and prevents orchidectomy-induced bone loss in rats.
   J Steroid Biochem Mol Biol, 103(1): 76-83. [Abstract] [Full-text]
3. Comprehensive evaluation of genetic variation in the IGF1 gene and risk of prostate cancer.
   Int J Cancer, 120(3): 539-42. [Abstract] [Full-text]
4. Differential expression of TRAIL and its receptors in benign and malignant prostate tissues.
   J Urol, 177(1): 359-64. [Abstract] [Full-text]
5. Quality of life for men receiving a second treatment for prostate cancer.
   J Urol, 177(1): 273-8; discussion 278-9. [Abstract] [Full-text]
6. Penile length changes in men treated with androgen suppression plus radiation therapy for local or locally advanced prostate cancer.
   J Urol, 177(1): 128-30. [Abstract] [Full-text]
7. High dose rate brachytherapy as a boost for the treatment of localized prostate cancer.
   J Urol, 177(1): 123-7; discussion 127. [Abstract] [Full-text]
8. Initial results using a running vesicourethral anastomosis following open radical retropubic prostatectomy.
   J Urol, 177(1): 118-22; discussion 122. [Abstract] [Full-text]
9. Changing nature of high risk patients undergoing radical prostatectomy.
   J Urol, 177(1): 113-7. [Abstract] [Full-text]
10. Prediction of indolent prostate cancer: validation and updating of a prognostic nomogram.
    J Urol, 177(1): 107-12; discussion 112. [Abstract] [Full-text]
11. Does body mass index affect preoperative prostate specific antigen velocity or pathological outcomes after radical prostatectomy?
    J Urol, 177(1): 102-6; discussion 106. [Abstract] [Full-text]
12. Dietary fatty acids correlate with prostate cancer biopsy grade and volume in Jamaican men.
    J Urol, 177(1): 97-101; discussion 101. [Abstract] [Full-text]
13. Bone health in men receiving androgen deprivation therapy for prostate cancer.
    J Urol, 177(1): 17-24. [Abstract] [Full-text]
14. Imaging of prostate cancer.
    Radiol Clin North Am, 45(1): 207-22. [Abstract] [Full-text]
15. Mitoxantrone-related acute myeloblastic leukaemia in a patient with metastatic hormone-refractory prostate cancer.
    Anticancer Drugs, 18(2): 233-5. [Abstract] [Full-text]
16. Effects of interactions of EGCG and Cd(2+) on the growth of PC-3 cells and their mechanisms.
    Food Chem Toxicol, 45(2): 244-9. [Abstract] [Full-text]
17. Survival associated with treatment vs observation of localized prostate cancer in elderly men.
    JAMA, 296(22): 2683-93. [Abstract] [Full-text]
18. Androgen deprivation in veterans with prostate cancer: implications for skeletal health.
    Ann Pharmacother, 40(12): 2107-14. [Abstract] [Full-text]
19. D,L-Sulforaphane-induced cell death in human prostate cancer cells is regulated by inhibitor of apoptosis family proteins and Apaf-1.
    Carcinogenesis, 28(1): 151-62. [Abstract] [Full-text]
20. Reactive oxygen species regulate insulin-induced VEGF and HIF-1alpha expression through the activation of p70S6K1 in human prostate cancer cells.
    Carcinogenesis, 28(1): 28-37. [Abstract] [Full-text]
21. Comprehensive expression analysis of L-dopa decarboxylase and established neuroendocrine markers in neoadjuvant hormone-treated versus varying Gleason grade prostate tumors.
    Hum Pathol, 38(1): 161-70. [Abstract] [Full-text]
22. Expression of CDX2 in benign tissue and adenocarcinoma of the prostate.
    Hum Pathol, 38(1): 72-8. [Abstract] [Full-text]
23. TSP1 and MMP9 genetic variants in sporadic prostate cancer.
    Cancer Genet Cytogenet, 172(1): 38-44. [Abstract] [Full-text]
24. Effect of 17beta-estradiol on apoptosis, IGF system components and gelatinases A and B in prostate cancer cells (PC-3).
    Clin Chim Acta, 377(1): 70-8. [Abstract] [Full-text]
25. Comparison between two commercially available chromogranin A assays in detecting neuroendocrine differentiation in prostate cancer and benign prostate hyperplasia.
    Clin Chim Acta, 377(1): 103-7. [Abstract] [Full-text]
26. Statin drugs and risk of advanced prostate cancer.
    J Natl Cancer Inst, 98(24): 1819-25. [Abstract] [Full-text]
27. Incremental value of multiplanar cross-referencing for prostate cancer staging with endorectal MRI.
    AJR Am J Roentgenol, 188(1): 99-104. [Abstract] [Full-text]
28. Combined use of diffusion-weighted MRI and 1H MR spectroscopy to increase accuracy in prostate cancer detection.
    AJR Am J Roentgenol, 188(1): 91-8. [Abstract] [Full-text]
29. Per-sextant localization and staging of prostate cancer: correlation of imaging findings with whole-mount step section histopathology.
    AJR Am J Roentgenol, 188(1): 84-90. [Abstract] [Full-text]
30. Mitogenic action of the androgen receptor sensitizes prostate cancer cells to taxane-based cytotoxic insult.
    Cancer Res, 66(24): 11998-2008. [Abstract] [Full-text]
31. The tumor metastasis suppressor gene Drg-1 down-regulates the expression of activating transcription factor 3 in prostate cancer.
    Cancer Res, 66(24): 11983-90. [Abstract] [Full-text]
32. Elevated E2F1 inhibits transcription of the androgen receptor in metastatic hormone-resistant prostate cancer.
    Cancer Res, 66(24): 11897-906. [Abstract] [Full-text]
33. Androgens regulate protein kinase Cdelta transcription and modulate its apoptotic function in prostate cancer cells.
    Cancer Res, 66(24): 11792-801. [Abstract] [Full-text]
34. DNA methylation pathway alterations in an autochthonous murine model of prostate cancer.
    Cancer Res, 66(24): 11659-67. [Abstract] [Full-text]
35. Prediction of seminal vesicle invasion in prostate cancer: incremental value of adding endorectal MR imaging to the Kattan nomogram.
    Radiology, 242(1): 182-8. [Abstract] [Full-text]
36. Human chorionic gonadotropin modulates prostate cancer cell survival after irradiation or HMG CoA reductase inhibitor treatment.
    Mol Pharmacol, 71(1): 259-75. [Abstract] [Full-text]
37. A phase I and pharmacokinetic study of silybin-phytosome in prostate cancer patients.
    Invest New Drugs, 25(2): 139-46. [Abstract] [Full-text]
38. Occupational risk factors for prostate cancer and benign prostatic hyperplasia: a case-control study in Western Australia.
    Occup Environ Med, 64(1): 60-5. [Abstract] [Full-text]
39. Image-guided in vivo dosimetry for quality assurance of IMRT treatment for prostate cancer.
    Int J Radiat Oncol Biol Phys, 67(1): 288-95. [Abstract] [Full-text]
40. Expression of vascular endothelial growth factor (VEGF) in locally invasive prostate cancer is prognostic for radiotherapy outcome.
    Int J Radiat Oncol Biol Phys, 67(1): 84-90. [Abstract] [Full-text]
41. Proctitis after external-beam radiotherapy for prostate cancer classified by Vienna Rectoscopy Score and correlated with EORTC/RTOG score for late rectal toxicity: results of a prospective multicenter study of 166 patients.
    Int J Radiat Oncol Biol Phys, 67(1): 78-83. [Abstract] [Full-text]
42. Five-year outcome of intraoperative conformal permanent I-125 interstitial implantation for patients with clinically localized prostate cancer.
    Int J Radiat Oncol Biol Phys, 67(1): 65-70. [Abstract] [Full-text]
43. Results of a phase II trial of transrectal ultrasound-guided permanent radioactive implantation of the prostate for definitive management of localized adenocarcinoma of the prostate (radiation therapy oncology group 98-05).
    Int J Radiat Oncol Biol Phys, 67(1): 39-47. [Abstract] [Full-text]
44. A magnetic resonance imaging study of prostate deformation relative to implanted gold fiducial markers.
    Int J Radiat Oncol Biol Phys, 67(1): 48-56. [Abstract] [Full-text]
45. 15-Year biochemical relapse free survival in clinical Stage T1-T3 prostate cancer following combined external beam radiotherapy and brachytherapy; Seattle experience.
    Int J Radiat Oncol Biol Phys, 67(1): 57-64. [Abstract] [Full-text]
46. Bypassing the learning curve in permanent seed implants using state-of-the-art technology.
    Int J Radiat Oncol Biol Phys, 67(1): 71-7. [Abstract] [Full-text]
47. Docetaxel-induced growth inhibition and apoptosis in androgen independent prostate cancer cells are enhanced by 1alpha,25-dihydroxyvitamin D3.
    Cancer Lett, 247(1): 122-9. [Abstract] [Full-text]
48. Aberrant expression of SWI/SNF catalytic subunits BRG1/BRM is associated with tumor development and increased invasiveness in prostate cancers.
    Prostate, 67(2): 203-13. [Abstract] [Full-text]
49. Estrogen signaling and disruption of androgen metabolism in acquired androgen-independence during cadmium carcinogenesis in human prostate epithelial cells.
    Prostate, 67(2): 135-45. [Abstract] [Full-text]
50. Sulfasalazine-induced cystine starvation: potential use for prostate cancer therapy.
    Prostate, 67(2): 162-71. [Abstract] [Full-text]
51. Inhibition of protein kinase CK2 leads to a modulation of androgen receptor dependent transcription in prostate cancer cells.
    Prostate, 67(2): 125-34. [Abstract] [Full-text]
52. Plasminogen activator inhibitor type-1 (PAI-1) polymorphism 4G/5G is associated with prostate cancer among men with a positive family history.
    Prostate, 67(2): 172-7. [Abstract] [Full-text]
53. Screening for prostate cancer at low PSA range: the impact of digital rectal examination on tumor incidence and tumor characteristics.
    Prostate, 67(2): 154-61. [Abstract] [Full-text]
54. A role for neurotensin in bicalutamide resistant prostate cancer cells.
    Prostate, 67(2): 190-202. [Abstract] [Full-text]
55. Prosaposin upregulates AR and PSA expression and activity in prostate cancer cells (LNCaP).
    Prostate, 67(2): 178-89. [Abstract] [Full-text]
56. Elevated levels of the mismatch repair protein PMS2 are associated with prostate cancer.
    Prostate, 67(2): 214-25. [Abstract] [Full-text]
57. Apoptosis induction and growth suppression by U19/Eaf2 is mediated through its ELL-binding domain.
    Prostate, 67(2): 146-53. [Abstract] [Full-text]
58. Phase II study of neoadjuvant androgen deprivation followed by external-beam radiotherapy with 9 months of androgen deprivation for intermediate- to high-risk localized prostate cancer.
    J Clin Oncol, 25(1): 77-84. [Abstract] [Full-text]
59. Increased risk of breast cancer associated with CHEK2*1100delC.
    J Clin Oncol, 25(1): 57-63. [Abstract] [Full-text]

© 2004-2012 Prostate Cancer Research Today. All Rights Reserved.